concentration was three times greater than that in the adult at 0.5 h and the difference between the two ages became greater as time passed, rising to tenfold at 8 h. The mean lung concentrations in adult and neonate were similar at 0.5, 1 and 2 h but at 4 and 8 h neonatal lung gentamicin levels were greater than those in the adult. Gentamicin was detectable in adult brain at 0.5 and 1 h only, values thereafter being insignificantly different from zero. In contrast the mean brain gentamicin concentration of the neonates rose progressively to a peak of 1.26 ng/mg at 4 h and had not fallen significantly at 8 h. In all tissues the extracellular space was significantly greater in the neonate but the degree of difference varied markedly, being greatest in the liver and least in the lung. The renal concentration of gentamicin in both adult and neonate was always in excess of the plasma concentration. In the adult there was no evidence of intracellular gentamicin in heart or muscle, but the mean lung concentration exceeded that in the lung extracellular space by 0.9-3.0 ng/mg at all times studied and the mean 'intracellular' gentamicin concentration in liver was 0.5, 1.5 and 1.4 ng/mg at 2, 4 and 8 h respectively. In neonatal lung and muscle 'intracellular' gentamicin was detectable from 2 h on and the concentration remained stable at 1.21-2.32 ng/mg. In liver 'intracellular' gentamicin was first detected at 4 h when the mean concentration was 1.6 ng/mg, but at 8 h this had risen to 3.71 ng/mg. Cardiac 'intracellular' gentamicin was present at 8 h in a low but significant concentration of 0.59 ng/mg.
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Azurophil granules of polymorphonuclear (PMN) leucocytes contain at least three neutral proteinases, two of which (elastase and cathepsin G) may play a role in the pathogenesis of glomerulonephritis ( Leucocytes of human peripheral blood from normal volunteers were separated into lymphocytes, PMN leucocytes and monocytes, sonicated and examined for total neutral proteinase (NP) (azocasein), elastase (Z-Ala-2-0 Nap and 3H elastin), cathepsin G (BZ-DL-Phe-2-0 Nap), cathepsin B (BZ-DL-Arg-2-naphthylamide) and cathepsin D (haemoglobin at pH 3.2). The results are shown in Table 1 .
Lymphocytes contain no NP or cathepsin B activity. PMN leucocytes contain large amounts of neutral proteinase(s) but no cathepsin B and therefore have the ability to degrade GBM only at physiological pH. Monocytes possess NP activity at a level considerably lower than PMN leucocytes. This activity contained both elastase and cathepsin G. In addition monocytes contained small amounts of cathepsin B, a thiol-dependent acid proteinase which also degrades GBM in uitro. Monocytes therefore contain proteinases which are capable of degrading GBM at acid and physiological pH. These findings suggest that the monocyte may also contribute to GBM damage in glomerulonephritis. Glanzmann's thrombasthenia is a bleeding disorder in which platelets do not aggregate in response to ADP added in uitro. It has been postulated that a defect may exist in the ADP receptor. Although a deficiency of a specific glycoprotein has been demonstrated in isolated platelet membranes (Nurden & Caen, 1974 , British Journal of Haematology, 28, 253), the binding of ADP to platelet membranes appears to be normal, so that the nature of the postulated receptor defect requires further clarification.
EVIDENCE FOR
Since the addition of ADP to platelets is associated with a series of readily measurable biochemical changes, we decided to examine the biochemical responses to ADP in Glanzmann's platelets.
Two patients with Glanzmann's disease were studied. Their platelets did not aggregate in response to ADP, adrenaline, collagen or the 11,9-epoxymethano-analogue of prostaglandin H,. The platelets also exhibited an impaired release of 14C-labelled serotonin in response to ADP. However, the cyclic nucleotide responses were indistinguishable from normal. Thus a rise in platelet 3':5'-cyclic AMP was observed in response to prostaglandin El (PGE,), and, despite the lack of aggregatory responses to ADP and adrenaline, both these agents caused a fall in cyclic AMP levels in platelets previously exposed to prostaglandin El. Moreover, the thrombin-and ADP-induced rises in malonyldialdehyde (MDA), a breakdown product of prostaglandin endoperoxides and thromboxane A,, were also present in Glanzmann's platelets. These results suggest that the receptor mechanism for ADP is at least partially intact in Glanzmann's platelets, since the cyclic nucleotide and MDA responses to ADP are still present. The defect seems more likely to reside in the later events in platelet aggregation that occur after generation of thromboxane A,. 
